Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 116

Similar articles for PubMed (Select 24388803)

1.

Avascular necrosis of bone after allogeneic hematopoietic cell transplantation in children and adolescents.

Li X, Brazauskas R, Wang Z, Al-Seraihy A, Baker KS, Cahn JY, Frangoul HA, Gajewski JL, Hale GA, Hsu JW, Kamble RT, Lazarus HM, Marks DI, Maziarz RT, Savani BN, Shah AJ, Shah N, Sorror ML, Wood WA, Majhail NS.

Biol Blood Marrow Transplant. 2014 Apr;20(4):587-92. doi: 10.1016/j.bbmt.2013.12.567. Epub 2014 Jan 2.

3.

Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.

Gürman G, Arat M, Ilhan O, Konuk N, Beksaç M, Celebi H, Ozcan M, Arslan O, Ustün C, Akan H, Uysal A, Koç H.

Cytotherapy. 2001;3(4):253-60.

PMID:
12171713
4.

Avascular necrosis following bone marrow transplantation: a case-control study.

Fink JC, Leisenring WM, Sullivan KM, Sherrard DJ, Weiss NS.

Bone. 1998 Jan;22(1):67-71.

PMID:
9437515
5.

Avascular necrosis of bone after allogeneic bone marrow transplantation: analysis of risk factors for 4388 patients by the Société Française de Greffe de Moëlle (SFGM).

Socié G, Cahn JY, Carmelo J, Vernant JP, Jouet JP, Ifrah N, Milpied N, Michallet M, Lioure B, Pico JL, Witz F, Molina L, Fischer A, Bardou VJ, Gluckman E, Reiffers J.

Br J Haematol. 1997 Jun;97(4):865-70.

PMID:
9217190
6.

Predictors of avascular necrosis of bone in long-term survivors of hematopoietic cell transplantation.

Campbell S, Sun CL, Kurian S, Francisco L, Carter A, Kulkarni S, Parker P, Karanes C, Forman SJ, Bhatia S.

Cancer. 2009 Sep 15;115(18):4127-35. doi: 10.1002/cncr.24474.

7.

Corticosteroid dose as a risk factor for avascular necrosis of the bone after hematopoietic cell transplantation.

McAvoy S, Baker KS, Mulrooney D, Blaes A, Arora M, Burns LJ, Majhail NS.

Biol Blood Marrow Transplant. 2010 Sep;16(9):1231-6. doi: 10.1016/j.bbmt.2010.03.008. Epub 2010 Mar 17.

8.

Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.

Moon JH, Sohn SK, Lambie A, Ellis L, Hamad N, Uhm J, Gupta V, Lipton JH, Messner HA, Kuruvilla J, Kim D.

Biol Blood Marrow Transplant. 2014 Apr;20(4):556-63. doi: 10.1016/j.bbmt.2014.01.010. Epub 2014 Jan 18.

9.

Avascular necrosis in long-term survivors after allogeneic or autologous stem cell transplantation: a single center experience and a review.

Tauchmanovà L, De Rosa G, Serio B, Fazioli F, Mainolfi C, Lombardi G, Colao A, Salvatore M, Rotoli B, Selleri C.

Cancer. 2003 May 15;97(10):2453-61.

10.

Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors.

Marr KA, Carter RA, Boeckh M, Martin P, Corey L.

Blood. 2002 Dec 15;100(13):4358-66. Epub 2002 Aug 22.

11.

Clostridium difficile infection after allogeneic hematopoietic stem cell transplant: strain diversity and outcomes associated with NAP1/027.

Kamboj M, Xiao K, Kaltsas A, Huang YT, Sun J, Chung D, Wu S, Sheahan A, Sepkowitz K, Jakubowski AA, Papanicolaou G.

Biol Blood Marrow Transplant. 2014 Oct;20(10):1626-33. doi: 10.1016/j.bbmt.2014.06.025. Epub 2014 Jun 25.

PMID:
24973628
12.
13.

Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation.

Hamilton BK, Rybicki L, Dean R, Majhail NS, Haddad H, Abounader D, Hanna R, Sobecks R, Duong H, Hill BT, Copelan E, Bolwell B, Kalaycio M.

Am J Hematol. 2015 Feb;90(2):144-8. doi: 10.1002/ajh.23882. Epub 2014 Nov 19.

PMID:
25353395
14.

Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.

Devillier R, Fürst S, El-Cheikh J, Castagna L, Harbi S, Granata A, Crocchiolo R, Oudin C, Mohty B, Bouabdallah R, Chabannon C, Stoppa AM, Charbonnier A, Broussais-Guillaumot F, Calmels B, Lemarie C, Rey J, Vey N, Blaise D.

Biol Blood Marrow Transplant. 2014 Mar;20(3):370-4. doi: 10.1016/j.bbmt.2013.11.030. Epub 2013 Dec 4.

15.

Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation.

Nakamae H, Yamane T, Hasegawa T, Nakamae M, Terada Y, Hagihara K, Ohta K, Hino M.

Am J Hematol. 2006 Jul;81(7):525-31.

PMID:
16755559
16.

Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.

Rosenbeck LL, Kiel PJ, Kalsekar I, Vargo C, Baute J, Sullivan CK, Wood L, Abdelqader S, Schwartz J, Srivastava S, Abonour R, Robertson MJ, Nelson RP Jr, Cornetta K, Fausel CA, Farag SS.

Biol Blood Marrow Transplant. 2011 Jun;17(6):916-22. doi: 10.1016/j.bbmt.2010.09.017. Epub 2010 Dec 4.

17.

Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation.

Shaughnessy PJ, Bolwell BJ, van Besien K, Mistrik M, Grigg A, Dodds A, Prince HM, Durrant S, Ilhan O, Parenti D, Gallo J, Foss F, Apperley J, Zhang MJ, Horowitz MM, Abhyankar S.

Bone Marrow Transplant. 2010 Jun;45(6):1068-76. doi: 10.1038/bmt.2009.307. Epub 2009 Nov 16.

18.

BK virus disease after allogeneic stem cell transplantation: a cohort analysis.

Rorije NM, Shea MM, Satyanarayana G, Hammond SP, Ho VT, Baden LR, Antin JH, Soiffer RJ, Marty FM.

Biol Blood Marrow Transplant. 2014 Apr;20(4):564-70. doi: 10.1016/j.bbmt.2014.01.014. Epub 2014 Jan 22.

19.

Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation.

Al-Hazzouri A, Cao Q, Burns LJ, Weisdorf DJ, Majhail NS.

Biol Blood Marrow Transplant. 2008 Jun;14(6):658-63. doi: 10.1016/j.bbmt.2008.03.008.

20.

Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.

Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, Micozzi A, Fenu S, Laurenti L, Donato V, De Felice L, Arcese W.

Haematologica. 2002 Jan;87(1):52-8.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk